The Type II Diabetes drug, Actos has received a black box label, has had a label change warning of a 40% increase in the risk for bladder cancer, and has been banned in France and Germany. Yet, Actos still remains on the market in the United States. Ringler Radio, host Larry Cohen joins colleague Martin...
|
|
Larry Cohen is the host of Ringler Radio and is the head of Ringler Associates operations in the Northeast....
The Type II Diabetes drug, Actos has received a black box label, has had a label change warning of a 40% increase in the risk for bladder cancer, and has been banned in France and Germany. Yet, Actos still remains on the market in the United States. Ringler Radio, host Larry Cohen joins colleague Martin C. Blount and Attorney Michael J. Miller, from The Miller Firm LLC, to discuss the side effects of the diabetes medication Actos, including its connection to bladder cancer, reaction of the FDA, and recent litigation.
Visit Ringler Associates to contact a consultant in your area about structured settlements.
Notify me when there’s a new episode!
| Published: | May 30, 2012 |
| Podcast: | Ringler Radio |
|
|
Ringler Radio |
Ringler Radio presents an unprecedented analysis of the latest news impacting the structured settlement profession.
Larry Cohen and guest and Ringler colleague, Phillip Krause discuss the benefits and advantages of going with a structured installment sale, and the reasons...
Mo Aziz discusses the settlement of the vegas shooting, the liability and negligence of MGM, and how this human tragedy led to a relatively...
Hon. Elizabeth Bonina takes a look at the use of technology in the Alternative Dispute Resolution arena and discusses how technology is improving the...
Jonathan Novak discuss Purdue Pharma’s bankruptcy filing and whether the remaining 25 states will agree to a settlement or take their fight to the courts.
Larry Cohen and Alan Pierce take a look at the history of workers’ comp and discuss technology’s impact on the workplace.
Joseph VanZandt discusses the recent news on sales, marketing, and labeling against JUUL, and how they've failed to warn off the products’ with high...
